OR WAIT null SECS
DSG is one of Ovation’s preferred providers for Phase I studies.
Malvern, PA-May 13, 2008-DSG (www.dsg-us.com), a leading EDC and clinical software technology provider, today announced that Ovation Pharmaceuticals (www.ovationpharma.com) is using DSG’s award-winning eCaseLink EDC software to conduct several Phase I clinical trials. DSG is one of Ovation’s preferred providers for EDC software for these studies.
To date, Ovation has used eCaseLink for five Phase I studies, and has seven Phase I studies underway or planned for 2008 and six Phase I studies planned for 2009.
“We looked at a number of vendors before choosing to work with DSG. We chose DSG’s eCaseLink for a number of our Phase I studies because it is very intuitive and user-friendly, and provides exceptionally clean data, as well as real-time data and monitoring. This translated directly into significant time and cost-savings for us,” said Robert Anders, vice president of Ovation’s clinical operations. “DSG supported very tight timelines for our Phase I studies.”
“We are pleased to work with Ovation, which continues to bring important therapies to market for very specific, high-need patient groups. The company has an impressive new product pipeline and we are proud to be a part of that process,” said Tony Varano, chief executive officer of DSG. “To complement our award-winning eCaseLink software, we are providing our EDC-focused data management services to increase their trial efficiencies even more.”